智通财经APP获悉,腾盛博药-B(02137)再涨超8%,截至发稿,涨8.21%,报2.11港元,成交额1167.83万港元。
消息面上,腾盛博药此前宣布,旗下全资子公司腾盛博药美国与健康元集团签订知识产权许可及技术转移协议,授予健康元集团在中国大陆、香港、澳门和台湾等大中华地区,研究、开发和商业化新药BRII-693的独占许可。根据协议,健康元将全面负责BRII-693在大中华区的开发、监管审批和商业化。腾盛博药美国已收取首付款,未来在达成相关里程碑事件时,将收到额外的开发和商业化里程碑付款,并将根据BRII-693的产品净销售额按约定比例获得销售分成。
公告称,BRII-693是一种在研新型合成脂肽,用于治疗多重耐药和广泛耐药(MDR/XDR)革兰氏阴性菌感染的重症患者。腾盛博药已从国家药监局药品审评中心取得临床试验许可,获准在中国开展BRII-693的一期药代动力学桥接研究,以支持未来在医院获得性细菌性肺炎/呼吸机相关细菌性肺炎患者中开展三期注册性试验。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.